CA2297907A1 - Recepteur beta d'oestrogenes humains - Google Patents

Recepteur beta d'oestrogenes humains Download PDF

Info

Publication number
CA2297907A1
CA2297907A1 CA002297907A CA2297907A CA2297907A1 CA 2297907 A1 CA2297907 A1 CA 2297907A1 CA 002297907 A CA002297907 A CA 002297907A CA 2297907 A CA2297907 A CA 2297907A CA 2297907 A1 CA2297907 A1 CA 2297907A1
Authority
CA
Canada
Prior art keywords
protein
antibody
mer
estrogens
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002297907A
Other languages
English (en)
Inventor
Rex Denton
Roland Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2297907A1 publication Critical patent/CA2297907A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne l'acide aminé et la séquence nucléotidique du gène complet du récepteur .beta. d'oestrogène (ER.beta.¿c?) ainsi que les séquences de protéine associées. Au vu de cette découverte, la présente invention concerne des procédés d'identification d'agents bloquant ou augmentant la régulation transcriptionnelle induite par l'ER.beta., des procédés permettant de déterminer si l'ER.beta.¿c?, ou ses isoformes, sont exprimés dans des tissus ou des cellules, et des procédés d'identification et d'utilisation des agents bloquant la régulation transcriptionnelle des gènes par l'ER.beta.¿c?, ou ses isoformes, qui, à leur tour, modulent d'autres processus biologiques et pathologiques.
CA002297907A 1997-07-28 1998-07-28 Recepteur beta d'oestrogenes humains Abandoned CA2297907A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5386997P 1997-07-28 1997-07-28
US5421097P 1997-07-30 1997-07-30
US60/054,210 1997-07-30
US60/053,869 1997-07-30
PCT/US1998/015539 WO1999005170A1 (fr) 1997-07-28 1998-07-28 RECEPTEUR β D'OESTROGENES ET ISOFORMES

Publications (1)

Publication Number Publication Date
CA2297907A1 true CA2297907A1 (fr) 1999-02-04

Family

ID=26732327

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002298053A Abandoned CA2298053A1 (fr) 1997-07-28 1998-07-28 Nouveau recepteur beta d'oestrogenes et ses isoformes
CA002297907A Abandoned CA2297907A1 (fr) 1997-07-28 1998-07-28 Recepteur beta d'oestrogenes humains

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002298053A Abandoned CA2298053A1 (fr) 1997-07-28 1998-07-28 Nouveau recepteur beta d'oestrogenes et ses isoformes

Country Status (4)

Country Link
EP (2) EP1001983A1 (fr)
JP (2) JP2001510691A (fr)
CA (2) CA2298053A1 (fr)
WO (2) WO1999005170A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
AU2001269690A1 (en) 2000-05-10 2001-11-20 David A. Sirbasku Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth

Also Published As

Publication number Publication date
WO1999005170A1 (fr) 1999-02-04
JP2001510690A (ja) 2001-08-07
WO1999005171A1 (fr) 1999-02-04
CA2298053A1 (fr) 1999-02-04
EP1001984A1 (fr) 2000-05-24
JP2001510691A (ja) 2001-08-07
WO1999005170A8 (fr) 1999-04-15
EP1001983A1 (fr) 2000-05-24

Similar Documents

Publication Publication Date Title
US6692925B1 (en) Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US5639616A (en) Isolated nucleic acid encoding a ubiquitous nuclear receptor
JP2975679B2 (ja) ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
JP5873034B2 (ja) エストロゲン受容体及び使用方法
JP2002507892A (ja) ヒト・アデニル酸シクラーゼのクローニングおよび特性評価
US20070020266A1 (en) Gpr54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
CA2297907A1 (fr) Recepteur beta d'oestrogenes humains
WO1999005170A9 (fr) RECEPTEUR β D'OESTROGENES ET ISOFORMES
JP2002514926A (ja) ヒト・アデニル酸シクラーゼのクローニングおよび特性評価
JP2003530109A (ja) エルビンをコードする遺伝子及びその診断及び治療的使用
JP2002505104A (ja) レクトメディン物質および方法
US6746867B1 (en) Mammalian mesoderm induction early response (MIER) gene family
JP2002525126A (ja) Ｔｒａｆ相互作用ｅｘｔ遺伝子ファミリーの新規遺伝子ｔｒｅｘ、並びにその診断及び治療への使用
JP3410178B2 (ja) 牛プロスタグランジンＦ２α受容体
JPWO2002088355A1 (ja) 新規なグアノシン三リン酸結合タンパク質共役型の受容体ｐｌａｃｅ６００２３１２およびその遺伝子、並びにそれらの製造および用途
JP2001521392A (ja) 新規なヒト腫瘍抑制遺伝子
US7888463B2 (en) Modulators of antiestrogen pharmacology
US7056694B1 (en) DNA encoding peripheral-type benzodiazipine receptor associated protein 7 and applications or methods of use
US20090018071A1 (en) Epididymis-specific receptor protein
US20020197670A1 (en) Membrane associated progesterone receptor
Chang et al. cDNA cloning, antibody production and immunohistochemical localization of the androgen receptor
JP2005522992A (ja) ヒトバニロイド受容体タンパク質及び前記タンパク質をコードするポリヌクレオチド配列
JP2002514924A (ja) ヒト・アデニル酸シクラーゼのクローニングおよび特性評価
US20030139589A1 (en) G protein coupled receptor A4
JPH1135493A (ja) 新規な抗エストロジェン遺伝子治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead